The decline in CD4 testing volumes has caused manufacturers to discontinue major point-of-care CD4 testing instruments. CD4 LFA testing could provide pragmatic and cost-effective screening for AHD. Therefore, implementation science and policy development should consider the interplay between diagnostic test performance, other attributes (eg, result turnaround time, accessibility, feasibility of decentralisation, cost-effectiveness, and diagnostic yield), and AHD prevalence. See the attached recent Viewpoint in Lancet HIV, May 2025
LFA based CD4 testing for advanced HIV disease_Lancet HIV 2025.pdf (226.8 KB)